AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21890884 — intervention group
Group type: EXPERIMENTAL
Intervention: Other endpoints (sedation)
Number of subjects: 0
Study 19478247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ministry of Health training program
Number of subjects: 0
Study 19478247 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16903592 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling needle therapy at the Urinary Bladder Channel line 1 and 2 and the Governor Vessel for 4 weeks
Number of subjects: 180
Study 16903592 — intervention group
Group type: COMPARATOR
Intervention: Clonopin 4-6 mg for 4 weeks
Number of subjects: 180
Study 16903592 — intervention group
Group type: EXPERIMENTAL
Intervention: Rolling needle therapy after 3 months follow-up
Number of subjects: 180
Study 16903592 — intervention group
Group type: COMPARATOR
Intervention: Clonopin after 3 months follow-up
Number of subjects: 180
Study 14684393 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (120 mg 3 times daily)
Number of subjects: 47
Study 14684393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11339779 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA) with 50 mg of 1% lidocaine
Number of subjects: 84
Study 11339779 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 84
Study 11339779 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia (SA)
Number of subjects: 84
Study 10423596 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ebastine after overnight fast
Number of subjects: 30
Study 10423596 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ebastine after low-fat breakfast
Number of subjects: 30
Study 10423596 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ebastine after high-fat breakfast
Number of subjects: 30
Study 10423596 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ebastine after overnight fast
Number of subjects: 30
Study 10423596 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ebastine after high-fat breakfast
Number of subjects: 30
Study 10423596 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 30
Study 10423596 — intervention group
Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 30
Study 7925757 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal changes in body composition and energy expenditure
Number of subjects: 0
Study 3295883 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (0.104 +/- 0.024 mg/kg)
Number of subjects: 44
Study 3295883 — intervention group
Group type: COMPARATOR
Intervention: Verapamil (8.4 +/- 3.4 mg IV)
Number of subjects: 44
Study 29073351 — intervention group
Group type: EXPERIMENTAL
Intervention: Belimumab at 10 mg/kg intravenously
Number of subjects: 20
Study 29073351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 27256562 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy group (instructed to choose foods representing a healthy diet)
Number of subjects: 187
Study 27256562 — intervention group
Group type: COMPARATOR
Intervention: Control group (instructed to serve themselves foods they would eat on a normal day)
Number of subjects: 187
Study 24731832 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate altitude hiking (1700 m)
Number of subjects: 71
Study 24731832 — intervention group
Group type: COMPARATOR
Intervention: Low altitude hiking (200 m)
Number of subjects: 71
Study 23899530 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib at 37.5mg daily until progression or a maximum of 6 months (arm B)
Number of subjects: 56
Study 23899530 — intervention group
Group type: COMPARATOR
Intervention: Observation (arm A)
Number of subjects: 56
Study 20839434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg) intravenously injected before 1 hour of cement injection
Number of subjects: 40
Study 20839434 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (2 mL) intravenously injected
Number of subjects: 40
Study 20839434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (20 mg) intravenously injected
Number of subjects: 40
Study 17426744 — intervention group
Group type: EXPERIMENTAL
Intervention: Spot urine samples
Number of subjects: 154
Study 17426744 — intervention group
Group type: COMPARATOR
Intervention: 24‐h urine samples
Number of subjects: 154
Study 15837829 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (375 mL; 39 grams alcohol)
Number of subjects: 0
Study 15837829 — intervention group
Group type: EXPERIMENTAL
Intervention: Beer (1125 mL; 41 grams alcohol)
Number of subjects: 0
Study 15837829 — intervention group
Group type: COMPARATOR
Intervention: Control-abstinence
Number of subjects: 0
Study 15837829 — intervention group
Group type: EXPERIMENTAL
Intervention: De-alcoholized red wine (375 mL)
Number of subjects: 0
Study 11796680 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 30
Study 11796680 — intervention group
Group type: COMPARATOR
Intervention: Flexibility-control
Number of subjects: 30
Study 10467610 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN as adjunct of medical therapy (Group I)
Number of subjects: 26
Study 10467610 — intervention group
Group type: EXPERIMENTAL
Intervention: TPN for in-hospital supportive care (Group II)
Number of subjects: 26
Study 7592151 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulus-choice procedure with two treatments based on Premack's principle
Number of subjects: 1
Study 1981422 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra guidance from a trained nurse
Number of subjects: 50
Study 1981422 — intervention group
Group type: COMPARATOR
Intervention: Routine information given by the physician during the medical visit
Number of subjects: 50
Study 6794419 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol Durules administered once daily at a daily dosage of 200 mg
Number of subjects: 17
Study 6794419 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol tablets administered twice daily at a daily dosage of 200 mg
Number of subjects: 17
Study 31521424 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational videos
Number of subjects: 207
Study 31521424 — intervention group
Group type: COMPARATOR
Intervention: Routine care (no educational videos)
Number of subjects: 207
Study 29709606 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy (NSPT) combined with antimicrobial photodynamic therapy (aPDT)
Number of subjects: 12
Study 29709606 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical periodontal therapy (NSPT)
Number of subjects: 12
Study 27589225 — intervention group
Group type: EXPERIMENTAL
Intervention: OPTIA
Number of subjects: 23
Study 27589225 — intervention group
Group type: COMPARATOR
Intervention: COBE
Number of subjects: 23
Study 27589225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both
Number of subjects: 23
Study 25298820 — intervention group
Group type: EXPERIMENTAL
Intervention: CDS tool
Number of subjects: 168
Study 25298820 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of risk prediction and bundled order set components
Number of subjects: 168
Study 22437556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based lunch meals fortified with low-iron (6.25 mg) micronutrients
Number of subjects: 258
Study 22437556 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice-based lunch meals fortified with high-iron (12.5 mg) micronutrients
Number of subjects: 258
Study 22437556 — intervention group
Group type: COMPARATOR
Intervention: Identical meals with unfortified rice
Number of subjects: 258
Study 20357328 — intervention group
Group type: EXPERIMENTAL
Intervention: Early reconstruction (< two weeks)
Number of subjects: 105
Study 20357328 — intervention group
Group type: COMPARATOR
Intervention: Delayed reconstruction (> four to six weeks)
Number of subjects: 105
Study 18792703 — intervention group
Group type: EXPERIMENTAL
Intervention: Ormocer-based composite (Admira)
Number of subjects: 35
Study 18792703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanohybrid resin composite (Tetric EvoCeram)
Number of subjects: 35
Study 18792703 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanofill resin composite (Filtek Supreme)
Number of subjects: 35
Study 18792703 — intervention group
Group type: COMPARATOR
Intervention: Microhybrid resin composite (Tetric Ceram)
Number of subjects: 35
Study 15695836 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial drain sponge dressing (polyhexamethylene biguanide)
Number of subjects: 10
Study 15695836 — intervention group
Group type: COMPARATOR
Intervention: Non-impregnated, nonwoven drain sponge dressing
Number of subjects: 10
Study 14508230 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol 10 mg once daily
Number of subjects: 24
Study 14508230 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg once daily
Number of subjects: 24
Study 11155731 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 day treatment
Number of subjects: 0
Study 11155731 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 day treatment
Number of subjects: 0
Study 8684102 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone 1000 mg daily and proguanil 400 mg daily for 3 days
Number of subjects: 142
Study 8684102 — intervention group
Group type: COMPARATOR
Intervention: Amodiaquine 600 mg on admission, 600 mg 24 h later, and 300 mg after a further 24 h
Number of subjects: 142
Study 14621737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nifedipine (group B)
Number of subjects: 68
Study 14621737 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CyA plus azathioprine (group C)
Number of subjects: 68
Study 3970747 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (penicillinase-resistant penicillin or erythromycin)
Number of subjects: 33
Study 3970747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3970747 — intervention group
Group type: EXPERIMENTAL
Intervention: Penicillinase-resistant antibiotic
Number of subjects: 33
Study 31595289 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise program (two sessions per week of individualized and progressive strength and balance exercises for 3 months)
Number of subjects: 85
Study 31595289 — intervention group
Group type: COMPARATOR
Intervention: Dual-task training group (simultaneous cognitive tasks with the same physical tasks as the multicomponent group for 3 months)
Number of subjects: 85
Study 29766470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) 1‐on‐1 intervention delivered by trained home visitors
Number of subjects: 120
Study 29766470 — intervention group
Group type: COMPARATOR
Intervention: Usual home visiting
Number of subjects: 120
Study 29766470 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB) 1‐on‐1 intervention
Number of subjects: 120
Study 26402571 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Carbohydrate Diet (LC)
Number of subjects: 24
Study 26402571 — intervention group
Group type: COMPARATOR
Intervention: Control Diet (CON)
Number of subjects: 24
Study 25863559 — intervention group
Group type: EXPERIMENTAL
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg)
Number of subjects: 341
Study 25863559 — intervention group
Group type: COMPARATOR
Intervention: Ledipasvir (90 mg) and sofosbuvir (400 mg) plus ribavirin
Number of subjects: 341
Study 22365595 — intervention group
Group type: EXPERIMENTAL
Intervention: Class II below knee elastic stockings (ESs, Medi UK Ltd.), fitted immediately and worn until pain-free and fully mobile.
Number of subjects: 36
Study 22365595 — intervention group
Group type: COMPARATOR
Intervention: Tubigrip, fitted immediately and worn until pain-free and fully mobile.
Number of subjects: 36
Study 20047800 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (62 Gy/20 fractions/5 weeks, 4 fractions per week)
Number of subjects: 168
Study 20047800 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation radiotherapy (80 Gy/40 fractions/8 weeks)
Number of subjects: 168
Study 20047800 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Number of subjects: 168
Study 20047800 — intervention group
Group type: COMPARATOR
Intervention: Conventional fractionation radiotherapy
Number of subjects: 168
Study 19040034 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted influenza subunit vaccine (FLUAD)
Number of subjects: 600
Study 19040034 — intervention group
Group type: COMPARATOR
Intervention: Conventional non-adjuvanted influenza subunit vaccine (Agrippal)
Number of subjects: 600
Study 15981669 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole PTH assay
Number of subjects: 25
Study 12589351 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (220 microg/d)
Number of subjects: 23
Study 12589351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 10475285 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (3.4 g over 5 days or 2.2 g over 24 hours)
Number of subjects: 84
Study 10475285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 8904945 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement and consumer-demand theory strategies for reducing cocaine use
Number of subjects: 0
Study 2065685 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 10
Study 2065685 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 10
Study 2065685 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 10
Study 6152563 — intervention group
Group type: EXPERIMENTAL
Intervention: zopiclone 7.5 mg
Number of subjects: 10
Study 6152563 — intervention group
Group type: COMPARATOR
Intervention: flunitrazepam 1 mg
Number of subjects: 10
Study 6152563 — intervention group
Group type: COMPARATOR
Intervention: triazolam 0.25 mg
Number of subjects: 10
Study 6152563 — intervention group
Group type: COMPARATOR
Intervention: lormetazepam 1 mg
Number of subjects: 10
Study 30686385 — intervention group
Group type: EXPERIMENTAL
Intervention: THPP and Enhanced Usual Care (EUC)
Number of subjects: 280
Study 30686385 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC) only
Number of subjects: 280
Study 29790581 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR0200 3 μg
Number of subjects: 0
Study 29790581 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR0200 6 μg
Number of subjects: 0
Study 29790581 — intervention group
Group type: EXPERIMENTAL
Intervention: PUR0200 9 μg
Number of subjects: 0
Study 29790581 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium HH 18 μg
Number of subjects: 0
Study 27401316 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg
Number of subjects: 307
Study 27401316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study 25201572 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated neonatal kit delivery and education on usage
Number of subjects: 0
Study 25201572 — intervention group
Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 0
Study 18977094 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT+MGd
Number of subjects: 554
Study 18977094 — intervention group
Group type: COMPARATOR
Intervention: WBRT
Number of subjects: 554
Study 18977094 — intervention group
Group type: EXPERIMENTAL
Intervention: WBRT+MGd (North American patients)
Number of subjects: 554
Study 16382755 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoangelac Plus with AA and DHA supplementation
Number of subjects: 27
Study 16382755 — intervention group
Group type: COMPARATOR
Intervention: Neoangelac without AA and DHA supplementation
Number of subjects: 27
Study 12146537 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered toothbrush (PB)
Number of subjects: 157
Study 12146537 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush (M)
Number of subjects: 157
Study 9160382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early amniocentesis (EA)
Number of subjects: 321
Study 9160382 — intervention group
Group type: COMPARATOR
Intervention: Chorionic villus sampling (CVS)
Number of subjects: 321
Study 8187256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral midazolam 0.5 mg.kg‐1
Number of subjects: 40
Study 8187256 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ketamine 5.0 mg.kg‐1
Number of subjects: 40
Study 2978036 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE‐Y graft
Number of subjects: 112
Study 2978036 — intervention group
Group type: COMPARATOR
Intervention: Dacron‐Y graft
Number of subjects: 112
Study 989091 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous heparin sodium therapy
Number of subjects: 41
Study 989091 — intervention group
Group type: COMPARATOR
Intervention: Intermittent (four‐hourly bolus) heparin therapy
Number of subjects: 41
Study 30659666 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/fluoride toothpaste (n:13)
Number of subjects: 26
Study 30659666 — intervention group
Group type: COMPARATOR
Intervention: Fluoride toothpaste (n:13)
Number of subjects: 26
Study 29283470 — intervention group
Group type: EXPERIMENTAL
Intervention: REMD‐477 (70 mg dose)
Number of subjects: 21
Study 29283470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27331913 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine-polyphenol supplement
Number of subjects: 12
Study 24269575 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (combined serotonin-norepinephrine reuptake inhibitor)
Number of subjects: 23
Study 24269575 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 23
Study 24269575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22266163 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (single oral dose)
Number of subjects: 18
Study 22266163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 21061756 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (MAL) 80 mg/g without occlusion followed by 25 J/cm2 red light exposure
Number of subjects: 44
Study 21061756 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (MAL) 80 mg/g with occlusion followed by 25 J/cm2 red light exposure
Number of subjects: 44
Study 21061756 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (MAL) 80 mg/g without occlusion followed by 37 J/cm2 red light exposure
Number of subjects: 44
Study 21061756 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylaminolevulinate (MAL) 80 mg/g with occlusion followed by 37 J/cm2 red light exposure
Number of subjects: 44
Study 17426414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 129
Study 17426414 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant treatment (paroxetine or clomipramine)
Number of subjects: 129
Study 17426414 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 15365215 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine (mCPP)
Number of subjects: 10
Study 15365215 — intervention group
Group type: EXPERIMENTAL
Intervention: sumatriptan
Number of subjects: 10
Study 15365215 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 10
Study 11394676 — intervention group
Group type: EXPERIMENTAL
Intervention: Primed test items
Number of subjects: 0
Study 11394676 — intervention group
Group type: COMPARATOR
Intervention: Unprimed test items
Number of subjects: 0
Study 11394676 — intervention group
Group type: EXPERIMENTAL
Intervention: Item and associative recognition
Number of subjects: 0
Study 11394676 — intervention group
Group type: EXPERIMENTAL
Intervention: Plurality and associative recognition
Number of subjects: 0
Study 9580313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9580313 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9 MU of rIL‐2 subcutaneously administered daily for 8 weeks
Number of subjects: 31
Study 9580313 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.8 MU of rIL‐2 subcutaneously administered daily for 8 weeks
Number of subjects: 31
Study 9580313 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.6 MU of rIL‐2 subcutaneously administered daily for 8 weeks
Number of subjects: 31
Study 7850601 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with a history of abuse
Number of subjects: 45
Study 7850601 — intervention group
Group type: COMPARATOR
Intervention: Nonmaltreated children
Number of subjects: 45
Study 3182542 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate (176 mmol/day)
Number of subjects: 11
Study 3182542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31836545 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided slow-paced respiration intervention using a portable biofeedback device (RESPeRATE) for 12 weeks, N=79
Number of subjects: 161
Study 31836545 — intervention group
Group type: COMPARATOR
Intervention: Control group using an identical device programmed to play nonrhythmic music for 12 weeks, N=82
Number of subjects: 161
Study 29999436 — intervention group
Group type: EXPERIMENTAL
Intervention: PAA + RFA
Number of subjects: 94
Study 29999436 — intervention group
Group type: COMPARATOR
Intervention: RFA
Number of subjects: 94
Study 27426936 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term DAPT (≤6 months)
Number of subjects: 11473
Study 27426936 — intervention group
Group type: COMPARATOR
Intervention: Long-term DAPT (≥1 year)
Number of subjects: 11473
Study 26630576 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Number of subjects: 40
Study 26630576 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 40
Study 26630576 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline mutant tumors (n = 10; PIK3CA mutations n = 8)
Number of subjects: 40
Study 23537017 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (1000 mg total)
Number of subjects: 12
Study 23537017 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sucrose)
Number of subjects: 12
Study 23537017 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 12
Study 21356018 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush T1 - bristles on the same plane, straight arrangement
Number of subjects: 27
Study 21356018 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothbrush T2 - bristles on different planes, straight arrangement
Number of subjects: 27